Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacestrant versus standard endocrine therapy for ctDNA-positive ER-positive/HER2-negative early breast cancer
NL-OMON59723Phase 3Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2023
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of elacestrant in breast cancer (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Distant metastasis-free survival. Started Nov 2023; status: recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON59723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59723.